4 unchanged sentences
Our limited common stock is not listed or traded on any stock exchange.
+Added: Performance Graph
+Added: The following performance graph related information shall not be deemed to be “soliciting material” or to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, nor shall such information be incorporated by reference into any future filing under the Exchange Act or the Securities Act of 1933, as amended, or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.
+Added: The following graph compares the cumulative total return on our common stock with the cumulative total return of the Nasdaq composite and the Nasdaq Biotechnology Index from February 6, 2020 (the first date that shares of our common stock were publicly traded on the Nasdaq Global Select Market) through December 31, 2021.
+Added: The graph assumes an investment of $100 on February 6, 2020, in each of the foregoing indices and in our common stock.
+Added: Data for each of the indices and our common stock assumes that all dividends were reinvested on the day of issuance, if any.
+Added: The comparisons are not intended to forecast or be indicative of future performance of our common stock.
Holders of Record
5 unchanged sentences
Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant.
−Removed: Certain Provisions of our Certificate of Incorporation and Bylaws
−Removed: During November 2020, the Bill & Melinda Gates Foundation Trust, Schrodinger Equity Holdings, LLC, D.
−Removed: Shaw & Co., L.P., D.
−Removed: Shaw Technology Development, LLC and D.
−Removed: Shaw Valence Portfolios, L.L.C.
−Removed: and their respective successors and affiliates ceased to collectively beneficially own (directly or indirectly) more than 40% of our outstanding shares of common stock and limited common stock.
−Removed: Accordingly, pursuant to the provisions in our certificate of incorporation and our bylaws, our directors may be removed only for cause and only by the affirmative vote of the holders of at least a majority of the voting power of all outstanding shares of common stock, and our stockholders may not take action by written consent in lieu of an annual or special meeting of stockholders.
Use of Proceeds
4 unchanged sentences
Recent Sales of Unregistered Securities
−Removed: Set forth below is information regarding issuances of shares of our common stock during the year ended December 31, 2020 that were not registered under the Securities Act of 1933, as amended, or the Securities Act, and that have not been otherwise described in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K.
−Removed: Issuances of Common Stock Upon Exchange of Limited Common Stock
−Removed: On November 24, 2020, the Bill & Melinda Gates Foundation Trust voluntarily converted 4,000,000 shares of limited common stock into 4,000,000 shares of common stock.
−Removed: The shares of common stock issued upon the conversion of the limited common stock described in this section were issued in reliance on the exemption provided by Section 3 (a)( 9 ) under the Securities Act.
+Added: Not applicable.
Issuer Purchases of Equity Securities
Not applicable.
−Removed: Selected Financial Data.
−Removed: You should read the following selected consolidated financial data together with our consolidated financial statements and the related notes, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other financial information included in this Annual Report.
−Removed: We have derived the consolidated statement of operations data for the years ended December 31, 2020 and 2019 and the consolidated balance sheet data as of December 31, 2020 and 2019 from our audited consolidated financial statements, which are included elsewhere in this Annual Report.
−Removed: The consolidated statement of operations data for the years ended December 31, 2018 and 2017 and the selected consolidated balance sheet data as of December 31, 2018 and December 31, 2017 are derived from our audited consolidated financial statements not included in this Annual Report.
−Removed: Our historical results are not necessarily indicative of results that should be expected in any future period.
−Removed: Year Ended December 31,
−Removed: (in thousands, except share and per share data)
−Removed: Consolidated Statements of Operations Data:
−Removed: Software products and services
−Removed: Drug discovery
−Removed: Total revenues
−Removed: Cost of revenues:
−Removed: Software products and services
−Removed: Drug discovery
−Removed: Total cost of revenues
−Removed: Operating expenses:
−Removed: Research and development
−Removed: Sales and marketing
−Removed: General and administrative
−Removed: Total operating expenses
−Removed: Loss from operations
−Removed: Other income (expense):
−Removed: Gain on equity investments
−Removed: Change in fair value
−Removed: Interest income
−Removed: Total other income (expense)
−Removed: Loss before income taxes
−Removed: Income tax expense (benefit)
−Removed: Net loss attributable to noncontrolling interest
−Removed: Net loss attributable to Schrödinger common
−Removed: and limited common stockholders
−Removed: Net loss per share attributable to Schrödinger common
−Removed: and limited common stockholders, basic and diluted:
−Removed: Weighted average common shares used to compute net
−Removed: loss per share attributable to common and limited common
−Removed: stockholders, basic and diluted (1) :
−Removed: Reflects the one-for-7.47534 reverse stock split of our common stock that became effective on January 24, 2020.
−Removed: (in thousands)
−Removed: Consolidated Balance Sheet Data
−Removed: Cash, cash equivalents, marketable securities, and
−Removed: restricted cash
−Removed: Working capital (2)
−Removed: Deferred revenue, current and long-term
−Removed: Convertible preferred stock
−Removed: Total stockholders’ equity (deficit)
−Removed: Working capital is current assets less current liabilities.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.